Literature DB >> 15888938

Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy.

David Andes1.   

Abstract

Animal models have been helpful in assessing a drug's potential application to treatment of humans. These controlled experiments allow description of the impact of a wide range of important treatment variables, including drug dose or concentration, dosing interval, pathogen, and host immune state. Animal models of mycoses are designed to address particular therapeutic questions. Some models are designed to screen multiple compounds in a rapid manner. Other models are selected to more closely mimic clinical infections. The following chapter will be limited to the description of a murine model of disseminated candidiasis in which in vitro results, pharmacokinetic properties, and a microbiological in vivo end point is used in the assessment of a wide variety of antifungal compounds.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888938     DOI: 10.1385/1-59259-943-5:111

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  17 in total

1.  In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Authors:  D Andes; D J Diekema; M A Pfaller; J Bohrmuller; K Marchillo; A Lepak
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

2.  Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation.

Authors:  Jeniel E Nett; Hiram Sanchez; Michael T Cain; Kelly M Ross; David R Andes
Journal:  Eukaryot Cell       Date:  2011-06-10

3.  Cm-p5: an antifungal hydrophilic peptide derived from the coastal mollusk Cenchritis muricatus (Gastropoda: Littorinidae).

Authors:  Carlos López-Abarrategui; Christine McBeth; Santi M Mandal; Zhenyu J Sun; Gregory Heffron; Annia Alba-Menéndez; Ludovico Migliolo; Osvaldo Reyes-Acosta; Mónica García-Villarino; Diego O Nolasco; Rosana Falcão; Mariana D Cherobim; Simoni C Dias; Wolfgang Brandt; Ludger Wessjohann; Michael Starnbach; Octavio L Franco; Anselmo J Otero-González
Journal:  FASEB J       Date:  2015-04-28       Impact factor: 5.191

4.  Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie VanHecker; Daniel Diekema; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

5.  Putative role of beta-1,3 glucans in Candida albicans biofilm resistance.

Authors:  Jeniel Nett; Leslie Lincoln; Karen Marchillo; Randall Massey; Kathleen Holoyda; Brian Hoff; Michelle VanHandel; David Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-11-27       Impact factor: 5.191

6.  Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan.

Authors:  Jeniel E Nett; Hiram Sanchez; Michael T Cain; David R Andes
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

7.  Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.

Authors:  Alexander J Lepak; Karen Marchillo; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

8.  In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Authors:  Miao Zhao; Alexander J Lepak; Brian VanScoy; Justin C Bader; Karen Marchillo; Jamie Vanhecker; Paul G Ambrose; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

9.  Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris.

Authors:  Milena Kordalewska; Annie Lee; Steven Park; Indira Berrio; Anuradha Chowdhary; Yanan Zhao; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

10.  Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.

Authors:  Alexander Lepak; Mariana Castanheira; Daniel Diekema; Michael Pfaller; David Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.